Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Has History Of Pushing Sponsors On Confirmatory Trials … Sometimes

Executive Summary

Even before a new law granted FDA authority to require studies be underway before accelerated approval, review divisions have, in some cases, given sponsors years of advance notice on expectations around study timing, according to a Pink Sheet review of NME accelerated approvals.

You may also be interested in...

Confirmatory Studies For Rare Diseases Shouldn’t Need To Start Before Accelerated Approval, Stakeholders Argue

Advocates and sponsors looking to shape implementation of US FDA’s new mandate want to ensure firms are not required to make significant investments in surrogate endpoints before they are validated.

GSK Defends Against US FDA Doubts About Jemperli Confirmatory Trial Feasibility

ODAC meeting on dostarlimab rectal cancer development program highlights issues at top of mind for the agency, including whether a proposed randomized trial in a different setting can be completed, timeline for development of evidence to verify clinical benefit, and challenges with using external controls for single-arm studies.

Accelerated Approval: US FDA Should Explain Why An Ongoing Trial Is Not Required

Having a confirmatory trial underway at the time of approval should be the ‘default expectation’ and the agency should publicly explain when and why it grants exceptions to this rule, experts said at a National Academies meeting on accelerated approval.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts